Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
Public ClinicalTrials.gov record NCT07843732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Adult Patients of African Descent With Biopsy-proven Central Centrifugal Cicatricial Alopecia (CCCA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluated the safety and efficacy of baricitinib 4 mg daily in adults of African descent with biopsy-proven central centrifugal cicatricial alopecia, a scarring alopecia for which no FDA-approved treatment exists. Participants received open-label baricitinib for 52 weeks at four sites in the United States. Scalp hair loss was assessed by the Investigator Global Assessment at baseline and by the Investigator Re-Assessment Score at each post-baseline visit, with patient-reported quality of life and scalp symptom measures collected in parallel.
Study identification
- NCT ID
- NCT07843732
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2024
- Primary completion
- Apr 27, 2026
- Completion
- Apr 27, 2026
- Last update posted
- Sep 27, 2026
2024 – 2026
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 02 | Marriottsville | Maryland | 21104 | — |
| Site 03 | Fairfax | Virginia | 22033 | — |
| Site 01 | McLean | Virginia | 22102 | — |
| Site 04 | Burlington | Wisconsin | 53105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Central Centrifugal Cicatricial Alopecia trials
Other public records listing Central Centrifugal Cicatricial Alopecia. Sorted by last update posted; newest first. Not a recommendation.
- NCT05416333: Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Active, not recruiting
- NCT07508488: Deucravacitinib in the Treatment of Cicatricial Alopecias Recruiting
- NCT07487948: Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris Recruiting
- NCT04764331: A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia Recruiting
- NCT06998433: Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07843732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2026 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07843732 live on ClinicalTrials.gov.